Scholarlink

<p>Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne pathogen of the <i>Nairoviridae</i> family, is classified as a high-risk biosafety level-4 (BSL-4) agent, which restricts its handling and limits mechanistic investigations. To overcome these challenges, we developed a CCHF pseudovirus as a safe and reliable surrogate for studying viral entry and evaluating antiviral candidates. Pseudovirus-based systems have proven valuable tools for elucidating viral infection mechanisms, conducting neutralization assays, and screening of small-molecule inhibitors. In the present study, a lentiviral packaging system incorporating CCHFV envelope glycoproteins (Gn and Gc) was established in HEK293T cells to generate infectious pseudovirions. Viral infectivity was quantified using a luciferase reporter assay. Cilnidipine, a clinically approved dual L-type and N-type calcium channel blocker with established antihypertensive activity, was investigated for its potential to inhibit CCHF pseudovirus entry in HEK293T and Huh-7 cells. Treatment with Cilnidipine resulted in a marked, dose-dependent reduction in luciferase signal, suggesting potent inhibition of pseudovirus entry at micromolar concentrations. Co-treatment assays further confirmed its inhibitory action at the early stages of infection. Overall, this study highlights Cilnidipine as a promising repurposed antiviral candidate targeting viral entry pathways. The findings provide a foundation for future mechanistic and pre-clinical evaluations aimed at developing effective therapeutics against CCHFV.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing Cilnidipine as an entry inhibitor against Crimean–Congo Hemorrhagic Fever pseudovirus infection

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Sujata Gupta,
  • Lekha Gandhi,
  • Basil A. Baby,
  • Gurleen Kaur,
  • Shubbir Ahmed,
  • Sweety Samal

摘要

Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne pathogen of the Nairoviridae family, is classified as a high-risk biosafety level-4 (BSL-4) agent, which restricts its handling and limits mechanistic investigations. To overcome these challenges, we developed a CCHF pseudovirus as a safe and reliable surrogate for studying viral entry and evaluating antiviral candidates. Pseudovirus-based systems have proven valuable tools for elucidating viral infection mechanisms, conducting neutralization assays, and screening of small-molecule inhibitors. In the present study, a lentiviral packaging system incorporating CCHFV envelope glycoproteins (Gn and Gc) was established in HEK293T cells to generate infectious pseudovirions. Viral infectivity was quantified using a luciferase reporter assay. Cilnidipine, a clinically approved dual L-type and N-type calcium channel blocker with established antihypertensive activity, was investigated for its potential to inhibit CCHF pseudovirus entry in HEK293T and Huh-7 cells. Treatment with Cilnidipine resulted in a marked, dose-dependent reduction in luciferase signal, suggesting potent inhibition of pseudovirus entry at micromolar concentrations. Co-treatment assays further confirmed its inhibitory action at the early stages of infection. Overall, this study highlights Cilnidipine as a promising repurposed antiviral candidate targeting viral entry pathways. The findings provide a foundation for future mechanistic and pre-clinical evaluations aimed at developing effective therapeutics against CCHFV.